TLPH (Talphera) Moat Score: 2/10 (As of Jun. 28, 2026)


TLPH Talphera Inc TLPH
34 GF Score
Price $1.03
! 3 Warning Signs
View Full Analysis

What is Talphera Moat Score?

Talphera TLPH -3.29% 34 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates TLPH with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Talphera ranks better than 81.65% on this metric.

Talphera has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Talphera has No Moat: Talphera Inc lacks significant market leadership, brand strength, or intellectual property. The company operates in a competitive industry with low barriers to entry, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Talphera might have No Moat - Very weak/transient advantages.

Talphera  (NAS:TLPH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Talphera Moat Score Related Terms

TLPH vs INIS, IXHL, ZYBT: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talphera Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Moat Score distribution charts can be found below:

* The bar in red indicates where Talphera's Moat Score falls into.


TLPH
34GF Score
Talphera Inc TLPH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Talphera (TLPH) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Talphera ranks #189 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Talphera's Moat Score too high?
Talphera's current Moat Score is 2. Based on the distribution chart, Talphera ranks #189 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Talphera has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Talphera's Moat Score compare to INIS and IXHL?
According to the Drug Manufacturers industry distribution chart, Talphera ranks #189 out of 1030 companies for Moat Score. This places Talphera in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Talphera's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talphera stock overvalued right now?
Talphera (TLPH) has a current Moat Score of 2. The current Moat Score is 2. Talphera's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Talphera (TLPH), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Talphera Business Description

Other Exchanges R5XA:Germany
Address 1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
34GF Score

Get the complete analysis for TLPH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price